{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:24:43Z","timestamp":1787142283079,"version":"build-2736575974"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":173,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome Investigator","award":["220295\/Z\/20\/Z"],"award-info":[{"award-number":["220295\/Z\/20\/Z"]}]},{"name":"Tom Walker PhD studentship"},{"name":"Acute Myeloid Leukaemia Research"},{"DOI":"10.13039\/100009828","name":"Cancer Research Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000723","name":"Tenovus Cancer Care","doi-asserted-by":"publisher","award":["PhD2019-28"],"award-info":[{"award-number":["PhD2019-28"]}],"id":[{"id":"10.13039\/501100000723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell receptors can sense cancer-associated changes in cellular proteins, lipids, metabolites, and stress pathways, enabling immune-mediated tumour elimination in some patients. These receptors underpin T-cell receptor-based immunotherapies, yet their isolation from clinical samples remains challenging due to labour-intensive workflows, dependence on prior antigen knowledge, and loss of cell viability. We developed an optimized flow cytometry-based assay, termed the T107 assay, to isolate viable cancer-reactive T-cells directly from clinical samples. Following short-term exposure to cancer cells, responding T-cells are identified by simultaneous surface detection of tumour necrosis factor and the degranulation marker CD107a, enabling recovery of live antigen-reactive cells for downstream analysis. The T107 assay enabled rapid identification of cancer-reactive T-cells from tumour-infiltrating lymphocyte products derived from melanoma and sarcoma patients. The assay supported phenotypic and functional characterization of \u03b1\u03b2 and \u03b3\u03b4 T-cell receptor populations, including CD4+ and CD8+ subsets, responding to both patient-specific and shared cancer antigens. Isolation of viable responding cells enabled high-resolution receptor sequencing, generation of functional T-cell clones, determination of antigen specificity and major histocompatibility complex restriction or independence. Paired receptors were engineered into primary T-cells to generate T-cell receptor-engineered products capable of recognizing multiple cancer types. The T107 assay provides a rapid and robust method for antigen-agnostic procurement of viable cancer-reactive T-cells and their receptors from clinical material. This approach removes key bottlenecks in T-cell receptor discovery and is expected to accelerate development of T-cell receptor-based immunotherapies across a broad range of cancers.<\/jats:p>","DOI":"10.1093\/immadv\/ltag009","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:40:45Z","timestamp":1780141245000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimized procurement of cancer-reactive T-cell receptors from clinical samples"],"prefix":"10.1093","volume":"6","author":[{"given":"Marine E","family":"Caillaud","sequence":"first","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rius","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9o","family":"Morin","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Rong","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Rogers","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Hick","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Centre for Cancer Immune Therapy, Herlev Hospital, Copenhagen University , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Samiul","family":"Hasan","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[{"name":"Centre for Cancer Immune Therapy, Herlev Hospital, Copenhagen University , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Szomolay","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]},{"name":"Systems Immunity Research Institute, Cardiff University Cardiff , Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3194-3135","authenticated-orcid":false,"given":"Andrew K","family":"Sewell","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]},{"name":"Systems Immunity Research Institute, Cardiff University Cardiff , Wales ,","place":["United Kingdom"]},{"name":"Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University , Kumamoto 8600811 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry","family":"Dolton","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine , Cardiff, Wales ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026081907311704600_ltag009-B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2567.2011.03515.x","article-title":"Structural and biophysical determinants of \u03b1\u03b2 T-cell antigen recognition","volume":"135","author":"Bridgeman","year":"2012","journal-title":"Immunology"},{"key":"2026081907311704600_ltag009-B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12622","article-title":"The T cell antigen receptor: the Swiss army knife of the immune system","volume":"181","author":"Attaf","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2026081907311704600_ltag009-B3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41590-019-0578-8","article-title":"Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1","volume":"21","author":"Crowther","year":"2020","journal-title":"Nat Immunol"},{"key":"2026081907311704600_ltag009-B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.coi.2020.12.002","article-title":"The burgeoning role of MR1-restricted T-cells in infection, cancer and autoimmune disease","volume":"69","author":"Crowther","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"2026081907311704600_ltag009-B5","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026081907311704600_ltag009-B6","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"2026081907311704600_ltag009-B7","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026081907311704600_ltag009-B8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat Med"},{"key":"2026081907311704600_ltag009-B9","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"2026081907311704600_ltag009-B10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"2026081907311704600_ltag009-B11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume-title":"Nat Rev Clin Oncol","author":"Cappell","year":"2023"},{"key":"2026081907311704600_ltag009-B12","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"2026081907311704600_ltag009-B13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","article-title":"Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors","volume":"37","author":"Harris","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"2026081907311704600_ltag009-B14","doi-asserted-by":"publisher","first-page":"1533033819831068","DOI":"10.1177\/1533033819831068","article-title":"The emerging world of TCR-T cell trials against cancer: a systematic review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"2026081907311704600_ltag009-B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"2026081907311704600_ltag009-B16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/DCR.0000000000001332","article-title":"Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: a systematic review and meta-analysis","volume":"62","author":"Kong","year":"2019","journal-title":"Dis Colon Rectum"},{"key":"2026081907311704600_ltag009-B17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1258\/ebm.2011.011007","article-title":"Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity","volume":"236","author":"Jochems","year":"2011","journal-title":"Exp Biol Med (Maywood)"},{"key":"2026081907311704600_ltag009-B18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-020-6668-z","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Cancer"},{"key":"2026081907311704600_ltag009-B19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/annonc\/mdt556","article-title":"Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study","volume":"25","author":"Dieci","year":"2014","journal-title":"Ann Oncol"},{"key":"2026081907311704600_ltag009-B20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"2026081907311704600_ltag009-B21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"2026081907311704600_ltag009-B22","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N Engl J Med"},{"key":"2026081907311704600_ltag009-B23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2026081907311704600_ltag009-B24","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2026081907311704600_ltag009-B25","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026081907311704600_ltag009-B26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026081907311704600_ltag009-B27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"2026081907311704600_ltag009-B28","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026081907311704600_ltag009-B29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2026081907311704600_ltag009-B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jim.2016.01.014","article-title":"T-cell libraries allow simple parallel generation of multiple peptide-specific human T-cell clones","volume":"430","author":"Theaker","year":"2016","journal-title":"J Immunol Methods"},{"key":"2026081907311704600_ltag009-B31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imm.12499","article-title":"More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers","volume":"146","author":"Dolton","year":"2015","journal-title":"Immunology"},{"key":"2026081907311704600_ltag009-B32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2567.2008.02848.x","article-title":"Tricks with tetramers: how to get the most from multimeric peptide-MHC","volume":"126","author":"Wooldridge","year":"2009","journal-title":"Immunology"},{"key":"2026081907311704600_ltag009-B33","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3389\/fimmu.2018.01378","article-title":"Optimised peptide-MHC multimer protocols for detection and isolation of autoimmune T-cells","volume":"9","author":"Dolton","year":"2018","journal-title":"Front Immunol"},{"key":"2026081907311704600_ltag009-B34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.4049\/jimmunol.1401785","article-title":"Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs","volume":"194","author":"Tungatt","year":"2015","journal-title":"J Immunol"},{"key":"2026081907311704600_ltag009-B35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nprot.2012.037","article-title":"Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers","volume":"7","author":"Andersen","year":"2012","journal-title":"Nat Protoc"},{"key":"2026081907311704600_ltag009-B36","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/nm.3359","article-title":"High-throughput identification of antigen-specific TCRs by TCR gene capture","volume":"19","author":"Linnemann","year":"2013","journal-title":"Nat Med"},{"key":"2026081907311704600_ltag009-B37","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00262-020-02568-x","article-title":"In vitro 4-1BB stimulation promotes expansion of CD8(+) tumor-infiltrating lymphocytes from various sarcoma subtypes","volume":"69","author":"Nielsen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2026081907311704600_ltag009-B38","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-16-3172","article-title":"Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNgamma signaling","volume":"77","author":"Donia","year":"2017","journal-title":"Cancer Res"},{"key":"2026081907311704600_ltag009-B39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-3083.2011.02640.x","article-title":"Characterization and comparison of \u2018standard\u2019 and \u2018young\u2019 tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution","volume":"75","author":"Donia","year":"2012","journal-title":"Scand J Immunol"},{"key":"2026081907311704600_ltag009-B40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jcyt.2014.02.004","article-title":"Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the wave bioreactor","volume":"16","author":"Donia","year":"2014","journal-title":"Cytotherapy"},{"key":"2026081907311704600_ltag009-B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181895","article-title":"MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-alpha chain","volume":"135","author":"Dolton","year":"2025","journal-title":"J Clin Invest"},{"key":"2026081907311704600_ltag009-B42","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"key":"2026081907311704600_ltag009-B43","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2012-06-437202","article-title":"Peptide length determines the outcome of TCR\/peptide-MHCI engagement","volume":"121","author":"Ekeruche-Makinde","year":"2013","journal-title":"Blood"},{"key":"2026081907311704600_ltag009-B44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","article-title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood"},{"key":"2026081907311704600_ltag009-B45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","article-title":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation","volume":"281","author":"Betts","year":"2003","journal-title":"J Immunol Methods"},{"key":"2026081907311704600_ltag009-B46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jim.2011.04.003","article-title":"Isolation of viable antigen-specific CD8+ T cells based on membrane-bound tumor necrosis factor (TNF)-alpha expression","volume":"369","author":"Haney","year":"2011","journal-title":"J Immunol Methods"},{"key":"2026081907311704600_ltag009-B47","doi-asserted-by":"publisher","first-page":"10917","DOI":"10.1073\/pnas.97.20.10917","article-title":"Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele","volume":"97","author":"Gnjatic","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026081907311704600_ltag009-B48","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00262-016-1897-3","article-title":"Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes","volume":"65","author":"Gloger","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2026081907311704600_ltag009-B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid\/round cell liposarcoma (SPEARHEAD-1): a multicentre, open-label, phase 2 trial","volume-title":"Lancet","author":"D'Angelo","year":"2024"},{"key":"2026081907311704600_ltag009-B50","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume-title":"N Engl J Med","author":"Hassel","year":"2023"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltag009\/68571305\/ltag009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/6\/1\/ltag009\/68571305\/ltag009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/6\/1\/ltag009\/68571305\/ltag009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:31:24Z","timestamp":1787139084000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltag009\/8713172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltag009","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2025,12,31]]},"article-number":"ltag009"}}